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Background. Although early-stage non-small-cell lung cancer (NSCLC) is considered a potentially curable disease following
complete resection, patients have a wide spectrum of survival according to stage (IB, II, IIIA). Within each stage, gene
expression profiles can identify patients with a higher risk of recurrence. We hypothesized that altered mRNA expression in
nine genes could help to predict disease outcome: excision repair cross-complementing 1 (ERCC1), myeloid zinc finger 1 (MZF1)
and Twist1 (which regulate N-cadherin expression), ribonucleotide reductase subunit M1 (RRM1), thioredoxin-1 (TRX1), tyrosyl-
DNA phosphodiesterase (Tdp1), nuclear factor of activated T cells (NFAT), BRCA1, and the human homolog of yeast budding
uninhibited by benzimidazole (BubR1). Methodology and Principal Findings. We performed real-time quantitative
polymerase chain reaction (RT-QPCR) in frozen lung cancer tissue specimens from 126 chemonaive NSCLC patients who had
undergone surgical resection and evaluated the association between gene expression levels and survival. For validation, we
used paraffin-embedded specimens from 58 other NSCLC patients. A strong inter-gene correlation was observed between
expression levels of all genes except NFAT. A Cox proportional hazards model indicated that along with disease stage, BRCA1
mRNA expression significantly correlated with overall survival (hazard ratio [HR], 1.98 [95% confidence interval (CI), 1.11-6];
P=0.02). In the independent cohort of 58 patients, BRCA1 mRNA expression also significantly correlated with survival (HR, 2.4
[95%CI, 1.01-5.92]; P=0.04). Conclusions. Overexpression of BRCA1 mRNA was strongly associated with poor survival in
NSCLC patients, and the validation of this finding in an independent data set further strengthened this association. Since
BRCA1 mRNA expression has previously been linked to differential sensitivity to cisplatin and antimicrotubule drugs, BRCA1
mRNA expression may provide additional information for customizing adjuvant antimicrotubule-based chemotherapy,
especially in stage IB, where the role of adjuvant chemotherapy has not been clearly demonstrated.
Citation: Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, et al (2007) BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung
Cancer. PLoS ONE 2(11): e1129. doi:10.1371/journal.pone.0001129
INTRODUCTION
In 2006 in Europe, there were an estimated 386,300 lung cancer
cases, with a substantially higher incidence in men than in
women[1]. Among completely resected non-small-cell lung cancer
(NSCLC) patients, 40% of stage I, 66% of stage II and 75% of
stage IIIA patients die within five years of resection[2], and the
benefit of adjuvant chemotherapy has not been demonstrated in
stage IB. In the ANITA randomized trial, 5-year survival for
patients with stage IB disease was 62% in the chemotherapy group
and 64% in the control group; corresponding rates were 52% and
39% for stage II patients and 42% and 26% for stage IIIA[3]. In
addition to disease stage, several studies have examined gene
expression profiles in NSCLC, identifying molecular subtypes
associated with patient outcome[4,5,6,7]. Gene expression signa-
tures ranging from five to 64 genes have been identified[6,7], and
cross-study comparisons have revealed significant, though in-
complete, agreement of patterns predicting outcome[4]. More-
over, the ability to interpret the meaning of the individual genes in
these signatures remains a challenge[8]. The gene expression
signatures identified genes mostly related to cancer metastasis[6]
but did not describe genes involved in DNA repair pathways.
Preclinical studies have demonstrated that a deficiency in any
one of the more than 30 genes involved in the nucleotide excision
repair (NER) pathway confers marked hypersensitivity to cisplat-
in[9]. Hypothesizing that elevated levels of NER genes could be
not only predictive but also prognostic markers, we chose to
examine the following genes, based on previous reports of their
predictive value: excision repair cross-complementing 1
(ERCC1)[10], BRCA1[11], human homolog of yeast budding
uninhibited by benzimidazole (BubR1)[12,13,14], myeloid zinc
finger 1 (MZF1)[15,16,17], ribonucleotide reductase subunit M1
(RRM1)[18,19,20], thioredoxin-1 (TRX1)[21,22], tyrosyl-DNA
phosphodiesterase (Tdp1)[23,24,25]. In addition, we examined
Twist[26,27] and nuclear factor of activated T cells (NFAT)[28,29],
which are involved in the invasion-metastasis process. (Further
details on the nine genes examined can be found in Text S1.)
None of these nine genes have been identified in gene expression
profiles associated with NSCLC patient outcome[4,5,6,7], with the
exception of TRX1, which was identified by proteomic analysis and
associated with poor survival[21]. In order to shed light on the
prognostic value of these genes, we have examined their expression
by real-time quantitative reverse transcriptase PCR (RT-PCR) in
126 completely resected NSCLC patients who did not receive
adjuvant chemotherapy and correlated the results with survival.
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Patients
NSCLC samples were obtained from 126 consecutive patients who
underwent curative pulmonary resection at the Medical University
of Gdansk (Gdansk, Poland) between 2000 and 2004, after
obtaining approval from the institutional review board of the
Medical University of Gdansk and patients’ signed informed
consent. The patients were 98 males and 28 females, with age at
diagnosis ranging from 37 to 77 years (median age, 64 years).
Seventy-one patients had stage I disease, 33 stage II, and 22 stage
IIIA. Twenty-seven patients had poorly differentiated, 74 moder-
ately differentiated, and 9 well-differentiated NSCLC; the remain-
ing 16 patients were unspecified. Eighty patients were smokers, 39
former smokers, and the remaining seven never-smokers. One
hundred and twenty-two patients underwent formal pulmonary
lobectomy or more, with systematic ipsilateral mediastinal lymph
node dissection; the four remaining patients underwent segmen-
tectomy due to poor pulmonary reserve. Stages were determined
after pathologic evaluation of resected specimens according to the
International System for Staging Lung Cancer[30] (Table S1).
None of the patients received adjuvant chemotherapy.
We validated the BRCA1 prognostic value in 58 stage IB-IIB
NSCLC patients who had undergone surgical resection at the
Azienda Ospedaliera Santa Maria (Terni, Italy) between February
1997 and December 2003, after obtaining approval from the
institutional review board of Azienda Ospedaliera Santa Maria
and patients’ signed informed consent. Patient characteristics are
shown in Table S1.
Gene expression analysis
Tumor samples from the 126 patients were obtained during
surgery as blocks of 1cm3 and snap-frozen in liquid nitrogen.
Tissues were stored in 280uC until total RNA was extracted with
AllPrep kits (Qiagen, Valencia, CA). Only tumor samples
containing more than 60% of tumor tissue on a microscopic
section were eligible for further processing. The concentration of
RNA was assessed in Nano-drop
TM and the quality of obtained
RNA was tested on agarose gel. First-strand cDNA was
synthesized from 1 mg of total RNA using the High-Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA). The
nine genes examined are shown in Table 1. Quantitative RT-PCR
reactions of each gene were done in an ABI PRISM 7900 HT
Sequence Detection System (Applied Biosystems).
Relative gene expression values were calculated by the DDCt
method using the Sequence Detection System (SDS) 2.1 software
(Applied Biosystems). The DDCt method gives the amount of
target gene normalized to an endogenous reference gene
(ribosomal 18S RNA) and relative to a calibrator sample (reference
for all samples; commercially available Normal Lung and Liver
Human RNA (Stratagene, La Jolla, CA). Primers for the nine
genes are listed in Table S2.
ERCC1, RRM1 and BRCA1 gene expression was assessed in
formalin-fixed, paraffin-embedded surgical specimens from the 58
Table 1. Nine genes examined in this study
..................................................................................................................................................
Official Symbol Name
Accession number
(transcript) (GEN ID) Aliases
ERCC1 excision repair cross-complementing rodent repair
deficiency, complementation group 1
NM_001983 COFS4, UV20
NM_202001
(2067)
MZF1 myeloid zinc finger 1 NM_198055 MZF-1, MZF1B, ZNF42, ZSCAN6, Zfp98
NM_003422
(7593)
Twist1 twist homolog 1 (acrocephalosyndactyly 3; Saethre-
Chotzen syndrome) (Drosophila)
NM_000474.3 ACS3, BPES2, BPES3, SCS, TWIST
(7291)
RRM1 ribonucleotide reductase M1 polypeptide NM_001033 R1, RIR1, RR1
(6240)
TXN thioredoxin NM_003329 DKFZp686B1993, MGC61975, TRX
(7295)
Tdp1 tyrosyl-DNA phosphodiesterase NM_018319 FLJ11090, MGC104252
NM_001008744
(55775)
NFATC2 nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 2
NM_173091 RP5-1009H6.1, KIAA0611, NFAT1, NFATP
NM_012340
(4773)
BRCA1 breast cancer 1, early onset NM_007294 BRCAI, BRCC1, IRIS, PSCP, RNF53
(672)
BUB1B BUB1 budding uninhibited by benzimidazoles 1
homolog beta (yeast)
NM_001211 BUB1beta, BUBR1, Bub1A, MAD3L, SSK1, hBUBR1
(701)
doi:10.1371/journal.pone.0001129.t001
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BRCA1 and Resected NSCLC
PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1129patients in the validation cohort. Using laser capture microdissec-
tion technique (Palm Microlaser, Oberlensheim, Germany)
ensured a minimum of 80% of tumor tissue. After standard tissue
sample deparaffinization using xylene and alcohols, samples were
lysed in a tris-chloride, EDTA, sodium dodecyl sulphate (SDS) and
proteinase K containing buffer. RNA was then extracted with
phenol-chloroform-isoamyl alcohol followed by precipitation with
isopropanol in the presence of glycogen and sodium acetate. RNA
was resuspended in DEPC water (Ambion Inc, Austin TX, USA)
and treated with DNAse I (Ambion Inc) to avoid DNA
contamination. cDNA was synthesized using M-MLV retro-
transcriptase enzyme. Template cDNA was added to Taqman
Universal Master Mix (Applied Biosystems) in a 12.5-ml reaction
with specific primers and probe for each gene. The primer and
probe sets were identical to those used in the frozen specimens; the
endogenous reference gene was b-actin. Quantification of gene
expression was performed using the ABI Prism 7900HT Sequence
Detection System (Applied Biosystems).
Statistical analyses
Median values and ranges were derived for quantitative variables
and mRNAgene expression. Qualitative variables were summarized
by means of absolute frequencies and percentages. The Kruskal-
Wallis test was used to check for normality. Differences in median
mRNA expression levels between histological types were assessed by
the U Mann-Whitney test. Spearman’s rank-correlation coefficient
(rho) was used to measure the correlations among gene expression
levels. We made an ap r i o r idecision to classify mRNA gene-
expression levels as high or low, using the minimum P value method
modified by Lausen and Schumacher[31]. The Bonferroni method
was used for the correction of the effectof multiplecomparisons, and
empirical P values for each gene were confirmed through 5000
permutationtests.Whennooptimalcut-offpoint wasfound,weused
the sample median for the analysis of time to relapse and survival.
Time to relapse and survival were calculated using Kaplan–Meier
estimates and differences between curves were tested using the log-
rank test. To choose an appropriate subset of genes for association to
any clinical variable (histology, stage and grade), we performed
aforwardandbackwardCoxregressionanalysis.Forallcalculations,
the tests performed were two-sided, significance was set at 5%, and
the power was 80%. Analyses were performed using Statistical
Package for the Social Sciences (SPSS) for Windows version 14
(SPSS Inc, Chicago, IL) and S-Plus 6.1 for Windows.
RESULTS
The median values of each gene for the entire group of samples
are shown in Table S3. Gene amplification was not successful in
a minority of samples for every transcript analyzed. There were
significant differences in expression according to histology for all
genes except NFAT, with higher levels observed in squamous cell
carcinomas than in adenocarcinomas (Table 2). There were no
differences in gene expression according to stage (Table S4). A
strong correlation was observed between expression levels of
different genes, for example, between levels of TRX and RRM1
(rho=0.52; P=0.0003) and between ERCC1 and BRCA1
(rho=0.62; P=0.0001) (Table 3).
Table 2. Gene expression according to histology
......................................................................
Squamous cell carcinoma Adenocarcinoma P*
Median (range) Median (range)
ERCC1 1.41 (0.45–7.34) 0.72 (0.23–2.45) 0.0001
MZF1 0.62 (0.06–6.72) 0.25 (0.03–1.49) 0.0001
Twist 10.37 (0.30–76.01) 2.50 (0.14–19.16) 0.0001
RRM1 2 (0.6–6.9) 1.2 (0.4–2.9) 0.0001
TRX 2.13 (0.40–11.88) 0.91 (0.31–7.94) 0.0001
Tdp1 1.7 (0.6–7.3) 1.3 (0.1–2.6) 0.02
NFAT 0.4 (0.1–2.3) 0.5 (0.1–1.8) 0.65
BRCA1 4.26 (0.55–18.48) 1.50 (0.09–8.08) 0.0001
BubR1 16.3 (1.4–90) 7 (0.8–25) 0.0001
*Mann-Whitney U
doi:10.1371/journal.pone.0001129.t002
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Table 3. Correlation between expression levels of the nine genes examined
..................................................................................................................................................
ERCC1 MZF1 Twist RRM1 TRX Tdp1 NFAT BRCA1
MZF1 0.70
P=0.0001
Twist 0.55 0.29
P=0.0001 P=0.001
RRM1 0.33 0.27 0.24
P=0.0001 P=0.004 P=0.01
TRX 0.39 0.20 0.25 0.52
P=0.0001 P=0.03 P=0.005 P=0.0001
Tdp1 0.25 0.25 0.10 0.65 0.34
P=0.007 P=0.008 P=0.26 P=0.0001 P=0.0001
NFAT 0.18 0.41 20.09 20.19 20.01 20.04
P=0.06 P=0.0001 P=0.36 P=0.04 P=0.88 P=0.66
BRCA1 0.62 0.58 0.29 0.62 0.48 0.47 0.04
P=0.0001 P=0.0001 P=0.001 P=0.0001 P=0.0001 P=0.0001 P=0.69
BubR1 0.12 0.30 0.23 0.83 0.47 0.63 20.17 0.69
P=0.0001 P=0.001 P=0.01 P=0.0001 P=0.0001 P=0.0001 P=0.06 P=0.0001
doi:10.1371/journal.pone.0001129.t003
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BRCA1 and Resected NSCLC
PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1129With a median follow-up of 29.7 months (range, 1.7–
65.9 months), overall event-free and median survival have not been
reached. When event-free and median survival was analyzed
according to expression levels of the nine genes, TRX and BRCA1
showed significant differences. Event-free survival for 21 patients
with low TRX levels has not been reached, while it was 32 months
(95%CI, ) for the remaining 93 patients with high levels (P=0.02).
For 77 patientswith low levelsof BRCA1,event-free survivalhas not
been reached, while it was 22 months (95%CI, 14.9–29 months) for
thosewithhighlevels(P=0.04)(TableS5,Fig.1).Event-freesurvival
curves according to expression of the other seven genes are shown in
Figure S1. Median survival for 24 patients with low TRX levels has
not been reached, while it was 39 months for the remaining 101
patients with high levels (P=0.03). For 83 patients with low levels of
BRCA1, median survival has not been reached, while it was
29 months (95%CI, 22.2–35.7 months) for those with high levels
(P=0.04) (Table 4, Fig. 1). Median survival curves according to
expression of the other seven genes are shown in Figure S2.
However, when only stage I patients were examined, event-free
survival was significantly different according to expression levels of
MZF1 and BRCA1 (Table S6, Fig. S3), and median survival was
significantly different according to expression levels of ERCC1,
MZF1, Twist and BRCA1 (Table S7, Fig. S4).
The Cox proportional hazards model selected pathological
stage IIIA and BRCA1 expression as independent prognostic
factors for survival. The hazard ratio (HR) was 7.91 (95%CI, 2.27-
27.54; P=0.001) for stage IIIA and 1.98 (95%CI, 1.11-6);
P=0.02) for BRCA1 expression (Table S8).
Figure 1. Event-free (A,B) and median (C,D) survival according to expression of TRX (A,C) and BRCA1 (B,D).
doi:10.1371/journal.pone.0001129.g001
BRCA1 and Resected NSCLC
PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1129Validation of BRCA1
The median follow-up of the 58 patients in the validation cohort was
40 months. According to the Cox proportional hazards model, the
HR for patients with high levels of BRCA1 was 2.4 (95%CI, 1.01-
5.92; P=0.04). There were no stage IIIA patients in this cohort.
DISCUSSION
Gene expression signatures have been shown to predict outcome in
resected stage I NSCLC[5,6], However, the use of microarrays is
limited due to the need for fresh-frozen tissue. RT-QPCR involving
a small number of genes offers a practical alternative, allowing for
accurate and reproducible quantification of results for RNA
obtained from small amounts of paraffin-embedded specimens.
The results of RT-QPCR performed on five[7] and eight[32] genes
correlated with outcomes of NSCLC[7] and lung adenocarcino-
ma[32] patients. We have examined the expression of ERCC1,
BRCA1, BubR1, MZF1, RRM1, TRX1 and Tdp1, involved in
DNA repair pathways, and of Twist and NFAT , related to
metastasis formation. In the multivariate model, only BRCA1 and
stage IIIA were identified as independent prognostic variables. In an
independent validation cohort of 58 stage IB-IIB NSCLC patients,
BRCA1 was confirmed as the only independent prognostic marker.
Patients whose tumors had high BRCA1 expression had
significantly worse survival and should be candidates for adjuvant
chemotherapy. In vitro studies have shown that BRCA1 can
regulate differential sensitivity to different classes of chemotherapy
agents[33]. The absence of BRCA1 results in high sensitivity to
cisplatin, whereas its presence increases sensitivity to antimicrotu-
bule agents[33]. Therefore, we believe that patients with the
highest expression levels should receive antimicrotubule, non-
platinum-based chemotherapy. We have carried out a pilot study
of customized adjuvant chemotherapy based on BRCA1 mRNA
levels in 88 completely resected stage II-IIIA NSCLC patients,
where those with the highest expression levels received adjuvant
docetaxel and those with lower levels received cisplatin-based
chemotherapy. The interim analysis shows that event-free survival
is similar in both groups. These findings support our previous
findings in stage II-IIIA patients who received neoadjuvant
gemcitabine/cisplatin, where those with the highest BRCA1 levels
had a dismal survival of 12 months[11].
No differences in expression levels of any of the nine genes were
observedaccordingtostageortumorsize(,4v s.4 cms).However,
ofallthe nine genes examined, onlyBRCA1 showed a trendtowards
influencing survival according to tumor size. In stage I NSCLC
patients, survival has been inversely correlated with tumor size[34].
In the present study, the univariate survival analysis showed that in
addition to BRCA1, ERCC1 and MZF1 significantly influenced
survival in stage I (Table S7, Fig. S4). These findings highlight the
potential role of ERCC1 and MZF1, which are highly correlated
with BRCA1, as strong prognostic markers in stage I NSCLC. Not
unexpectedly,however,consideringthehighcorrelationbetweenthe
expression levels of these three genes (Table 3), when all three genes
were combined, no further improvement over the prognostic value
of BRCA1 alone was observed.
Although the mechanisms by which some of the nine genes
examined affect patient prognosis is not very clear, overexpres-
sion of ERCC1 and RRM1 seems to be oncogene-
driven[35,36,37,38,39]. BRCA1 methylation and abrogation of
BRCA1 mRNA has been found in sporadic breast cancers[40] but
very rarely in NSCLC[41]. In some sporadic breast cancers, the
poor outcome associated with BRCA1 methylation and low levels
of expression could be explained by MYC amplification[42].
Other studies, using the monoclonal antibody 8F1[43] have
reported that the presence of ERCC1 protein is a prognostic
marker of survival in early NSCLC and a predictor of outcome to
adjuvant cisplatin-based chemotherapy; however, in a prior study
in gastric cancer[44], it was unclear whether the poor clinical
response of patients whose tumors had high pretreatment mRNA
levels of ERCC1 resulted from tumor cell resistance to cisplatin-
based chemotherapy or from a more aggressive tumor biology.
Moreover, in ERCC1-positive normal human fibroblasts and cells
from patients with inherited mutations in ERCC1, ERCC1 is not
the principal antigen recognized by the 8F1 antibody on
immunostaining[45]. Furthermore, in another study, ERCC1
protein status did not correlate with survival in stage IV
NSCLC[46], while in a trial of customized cisplatin based on
ERCC1 mRNA expression, response rate was 39% in the control
arm and 50% in the customized arm (P=0.02)[47].
In summary, our study indicates that firstly, BRCA1 is closely
related to ERCC1, RRM1 and other genes like MZF1, but stands
out as the most significant prognostic marker of relapse. We
hypothesize that patients with high BRCA1 levels will benefit from
antimicrotubule-based–but not cisplatin-based–chemotherapy.
Secondly, high levels of these transcripts confer a higher risk of
relapse, in contrast to what has been reported by other
investigators, which highlights the need for further research in
Table 4. Median survival according to gene expression
......................................................................
N* Median Survival (months) 95% CI P
ERCC1 0.89
#1.24 61 NR -
.1.24 62 39.5 -
MZF1 0.05
#0.5 56 NR -
.0.5 66 33 21.9–44.1
Twist 0.39
#7.75 61 NR -
.7.75 61 NR -
RRM1 0.11
#1.65 61 NR -
.1.65 60 33.9 24–43.9
TRX 0.03
#0.8 24 NR -
.0.8 101 39 -
Tdp1 0.88
#1.57 60 NR -
.1.57 61 41.3 -
NFAT 0.51
#0.46 61 NR -
.0.46 61 33.9 -
BRCA1 0.01
#58 3 N R -
.5 40 29 22.2–35.7
BubR1 0.41
#12.28 61 NR -
.12.28 61 36.7 -
*Survival data is not available for some patients. Gene amplification was not
successfully performed in all samples for all genes.
NR=not reached
doi:10.1371/journal.pone.0001129.t004
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1129this area to elucidate the predictive role of these NER-related
genes and to correctly customize treatment (Fig. S5). Although the
population in our study was skewed to male smokers with squamous
cell carcinoma, our results warrant further investigation to confirm
theirapplicabilitytootherhistological subsetsofNSCLC,Inorderto
shed further light on these issues, we are planning to examine
BRCA1, ERCC1, MZF1 and RRM1 expression in 200 tumor
specimens from the ANITA study[3] and in 620 patients included in
the Spanish Lung Cancer Group NATCH trial of neoadjuvant vs
adjuvant chemotherapy vs surgery alone.
SUPPORTING INFORMATION
Figure S1 Event-free survival according to the expression of
ERCC1 (A), MZF1 (B), Twist (C), RRM1 (D), Tdp1 (E), NFAT
(F), and BubR1 (G)
Found at: doi:10.1371/journal.pone.0001129.s001 (0.09 MB TIF)
Figure S2 Median survival according to the expression of
ERCC1 (A), MZF1 (B), Twist (C), RRM1 (D), Tdp1 (E), NFAT
(F), and BubR1 (G)
Found at: doi:10.1371/journal.pone.0001129.s002 (0.09 MB TIF)
Figure S3 Event-free survival curves for stage I patients
according to gene expression levels of the nine genes
examined
Found at: doi:10.1371/journal.pone.0001129.s003 (0.10 MB TIF)
Figure S4 Median survival curves for stage I patients according
to gene expression levels of the nine genes examined
Found at: doi:10.1371/journal.pone.0001129.s004 (0.10 MB TIF)
Figure S5 Contradictory findings leading to opposed strategies
of customizing adjuvant chemotherapy. Olaussen et al (NEJM
2006;355:983-991) report that the lack of ERCC1protein implies
a higher risk of relapse and a greater sensitivity to cisplatin-based
chemotherapy. (Cisplatin sensitivity based on lack of ERCC1
expression has been demonstrated in preclinical and clinical
studies.) Our findings indicate that a higher risk of relapse is
related to high levels of several transcripts, including ERCC1.
These patients could be resistant to cisplatin and sensitive to
taxanes or other antimicrotubule drugs
Found at: doi:10.1371/journal.pone.0001129.s005 (0.13 MB TIF)
Table S1 Patient characteristics for principal cohort (N=126)
and for validation cohort (N=58)
Found at: doi:10.1371/journal.pone.0001129.s006 (0.04 MB
DOC)
Table S2 Primers and probes for the nine genes examined
Found at: doi:10.1371/journal.pone.0001129.s007 (0.03 MB
DOC)
Table S3 Relative gene expression values
Found at: doi:10.1371/journal.pone.0001129.s008 (0.03 MB
DOC)
Table S4 Gene expression according to disease stage
Found at: doi:10.1371/journal.pone.0001129.s009 (0.04 MB
DOC)
Table S5 Event-free survival according to gene expression levels
Found at: doi:10.1371/journal.pone.0001129.s010 (0.06 MB
DOC)
Table S6 Event-free survival in stage I patients according to
gene expression levels
Found at: doi:10.1371/journal.pone.0001129.s011 (0.06 MB
DOC)
Table S7 Median survival for stage I patients according to gene
expression levels
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